EnzymeRx Provides a Clinical Update on Pegsitacase
News Feb 23, 2010
EnzymeRx, LLC has announced completion of the enrollment of its first clinical trial of pegsitacase (formerly called Uricase PEG 20), and the recent launch of a second clinical study.
Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.
The completed trial was a phase 1 safety, pharmacokinetic and pharmacodynamic study of single ascending intravenous doses of pegsitacase (study details available at ClinicalTrials.gov).
The study sequentially enrolled five cohorts of four subjects each, with each cohort receiving escalating single doses of pegsitacase administered by intravenous infusion over one hour, without any premedication.
Tony Fiorino, MD, PhD, President and Chief Executive Officer of EnzymeRx, remarked: “It is truly gratifying to have completed enrollment in our first clinical study of pegsitacase. The drug was extremely well tolerated in these subjects, with no infusion reactions, and we are very pleased with the potency and duration of uric acid-lowering that we have seen thus far. We plan to present the results from this study at a medical conference later in 2010.”
The recently launched phase 1b trial is studying the safety, pharmacokinetics and pharmacodynamics of single and multiple intramuscular doses of pegsitacase (study details available at ClinicalTrials.gov).
In this study, subjects are enrolling into escalating dose cohorts receiving either single doses or three biweekly doses of pegsitacase. Data from this study are expected later this year.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018